Markets
Palantir
(Tasos Katopodis/Getty Images for Palantir)

Palantir surges as it deepens its ties to the federal government

Shares of the software firm, up over 300% this year, have become a favorite of retail traders.

12/3/24 12:31PM

Palantir is a top performer today, after announcing a new government security designation that would expand its ability to sell its cloud services to the US government. The designation, known as FedRAMP High Baseline, “enables the U.S. government to process the most sensitive unclassified workloads in Palantir’s cloud offering,” the company said in a statement.

Such bureaucratic updates typically wouldn’t be the stuff to get tech-stock traders super excited.

But the sales to government — particularly the prospect that the company could benefit from an incoming Trump administration with close ties to powerful right-wing tech billionaires Elon Musk and Peter Thiel, who is a cofounder of Palantir — are a huge part of the story that’s turned Palantir into a widely traded retail favorite over the last year.

On a raw dollar basis, the company’s sales to governments are larger and growing faster — $408 million in Q3, up 32.5% — than its commercial division, worth $317 million, up 26.4% in Q3 compared to the prior year. (Palantir’s US government business rose an even faster 40% in Q3, the company told analysts during a conference call.)

But sales are going to have to be genuinely massive to justify the valuations the stock market is putting on the company. In context, right now the collective wisdom of the world capital is putting a forward price-to-sales multiple on Palantir of an insane 45x.

To put that in perspective, here’s how Palantir’s current valuation compares with peak price-to-book multiples with some of the most notable and beloved tech companies in recent decades.

Seems like there’s some unrealistic enthusiasm baked into the price! But for now, Palantirians are enjoying their current status as kings of the S&P 500. Palantir’s more than 300% gain currently makes it the best-performing stock of the index this year — just ahead of Vistra — though it only joined the blue chip index in September.

More Markets

See all Markets
markets

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

markets

UNH rises after saying it plans to reiterate outlook

UnitedHealth rose 2% in early trading after it disclosed that it plans to reiterate its full-year earnings outlook when it meets with investors this week.

The company said on July 29 that it was expects to report annual adjusted earnings per share of at least $16. The company had previously pulled full-year guidance and prior to that withdrawal, had told investors it expected to see earnings of $26 to $26.50 per share.

Currently, a analysts polled by FactSet are penciling in $16.23, compared to $17.21 before the guidance came down.

UnitedHealth has had a tumultuous year as he industry has been hit with rising costs of care, and UnitedHealth specifically has been hit with investigations into its Medicare Advantage practices. It recently got a boost after Warren Buffett's Berkshire Hathaway revealed that it's built a stake in the company

markets

T-Mobile and other wireless carriers tumble on SpaceX’s purchase of spectrum licenses from EchoStar

T-Mobile is the worst-performing S&P 500 constituent in early trading, off 5.2% as of 8:27 a.m. ET.

The reason why? SpaceX purchased a pair of spectrum licenses from EchoStar for roughly $17 billion, and as such, SpaceX might no longer need to rely as heavily on T-Mobile going forward.

In August 2022, T-Mobile and SpaceX announced a partnership in which the carrier would help SpaceX’s Starlink provide mobile connectivity from space. The first such satellites launched in January 2024, and T-Mobile ran an ad during the 2025 Super Bowl touting a beta trial of Starlink-powered satellite texting.

However, other wireless providers like AT&T and Verizon are also down (4.5% and 4.2%, respectively) ahead of the open, so this may also simply be a selloff linked to the wireless providers not being the ones to purchase these valuable spectrum licenses themselves — even though AT&T struck a deal with EchoStar in late August to purchase $23-billion in spectrum assets.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.